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OBJECTIVE: The aim of this systematic review was to report pregnancy and perinatal outcomes of coronavirus spectrum infections, and
particularly coronavirus 2019 (COVID-19) disease because of severe acute respiratory syndromeecoronavirus-2 infection during pregnancy.
DATA SOURCES: Medline, Embase, Cinahl, and Clinicaltrials.gov databases were searched electronically utilizing combinations of word
variants for coronavirus or severe acute respiratory syndrome or SARS or Middle East respiratory syndrome or MERS or COVID-19 and
pregnancy. The search and selection criteria were restricted to English language.
STUDY ELIGIBILITY CRITERIA: Inclusion criteria were hospitalized pregnant women with a confirmed coronavirus relatedeillness, defined
as severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), or COVID-19.
STUDY APPRAISAL AND SYNTHESIS METHODS: We used meta-analyses of proportions to combine data and reported pooled pro-
portions, so that a pooled proportion may not coincide with the actual raw proportion in the results. The pregnancy outcomes observed
included miscarriage, preterm birth, preeclampsia, preterm prelabor rupture of membranes, fetal growth restriction, and mode of delivery.
The perinatal outcomes observed were fetal distress, Apgar score<7 at 5 minutes, neonatal asphyxia, admission to a neonatal intensive
care unit, perinatal death, and evidence of vertical transmission.
RESULTS: Nineteen studies including 79 hospitalized women were eligible for this systematic review: 41 pregnancies (51.9%) affected by COVID-
19, 12 (15.2%) byMERS, and 26 (32.9%) by SARS. An overt diagnosis of pneumonia wasmade in 91.8%, and themost common symptomswere
fever (82.6%), cough (57.1%), and dyspnea (27.0%). For all coronavirus infections, the pooled proportion of miscarriage was 64.7% (8/12; 95%
confidence interval, 37.9-87.3), although reported only for women affected by SARS in two studies with no control group; the pooled proportion of
pretermbirth<37weekswas 24.3% (14/56; 95%confidence interval, 12.5e38.6); premature prelabor rupture ofmembranes occurred in 20.7%
(6/34; 95% confidence interval, 9.5e34.9), preeclampsia in 16.2% (2/19; 95% confidence interval, 4.2e34.1), and fetal growth restriction in
11.7% (2/29; 95% confidence interval, 3.2e24.4), although reported only for women affected by SARS; 84% (50/58) were delivered by cesarean;
the pooled proportion of perinatal death was 11.1% (5/60; 95% confidence interval, 84.8e19.6), and 57.2% of newborns (3/12; 95% confidence
interval, 3.6e99.8) were admitted to the neonatal intensive care unit.When focusing on COVID-19, themost common adverse pregnancy outcome
was preterm birth<37weeks, occurring in 41.1% of cases (14/32; 95% confidence interval, 25.6e57.6), while the pooled proportion of perinatal
death was 7.0% (2/41; 95% confidence interval, 1.4e16.3). None of the 41 newborns assessed showed clinical signs of vertical transmission.
CONCLUSION: In hospitalized mothers infected with coronavirus infections, including COVID-19, >90% of whom also had pneumonia,
preterm birth is the most common adverse pregnancy outcome. COVID-19 infection was associated with higher rate (and pooled pro-
portions) of preterm birth, preeclampsia, cesarean, and perinatal death. There have been no published cases of clinical evidence of vertical
transmission. Evidence is accumulating rapidly, so these data may need to be updated soon. The findings from this study can guide and
enhance prenatal counseling of women with COVID-19 infection occurring during pregnancy, although they should be interpreted with
caution in view of the very small number of included cases.
Key words: coronavirus, coronavirus 2019, infection, Middle East respiratory syndrome, pregnancy, severe acute respiratory syndrome,
severe acute respiratory syndromeecoronavirus-2
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AJOG MFM at a Glance
Why was this study published?
Coronavirus 2019 (COVID-19) disease secondary to severe acute respiratory
syndromeecoronavirus-2 infection is a worldwide pandemic with an increasing
number of confirmed cases every day. Little is known about the effect of coro-
navirus (CoV)-related infections during pregnancy.
Key findings
Hospitalized pregnant women with COVID-19 infection had higher rates (and
pooled proportions) of preterm birth, preeclampsia, cesarean delivery, and
perinatal death. These findings should be interpreted with caution in view of the
very small number of included cases.
What does this add to what is known?
This is the first systematic review exploring pregnancy and perinatal outcomes of
CoV infections occurring during pregnancy. Although limited, these data can
guide and enhance prenatal counseling of women with COVID-19 infection
occurring during pregnancy. Evidence is accumulating rapidly, so these data may
need to be updated soon.
Systematic Revieworonavirus (CoV) is an enveloped,C positive-stranded ribonucleic acid
(RNA) virus of the family of Corona-
viridae and belonging to the Nidovirales
order,1 generally causing respiratory and
gastrointestinal infections that might
range from mild, self-limiting condi-
tions to more serious disorders, such
as viral pneumonia with systemic
impairment.2
In the last 2 decades, CoV has been
responsible for 2 large epidemics: the
severe acute respiratory syndrome
(SARS) that infected 8098 people with a
case-fatality rate of about 10.5%3 and the
Middle East respiratory syndrome
(MERS) with a total of 2519 laboratory-
confirmed cases and a case fatality rate of
34.4%.4
Towards the end of 2019, a novel
mutation of CoV (labeled as SARSe
coronavirus-2) was identified as the
cause of a severe respiratory illness,
called coronavirus 2019 (COVID-19),
that typically presents with fever and
cough.5 Infected people show abnormal
findings at diagnostic imaging, sugges-
tive for pneumonia.
After beginning as an epidemic in
China, COVID-19 infection has rapidly
spread in many other countries, and the
number of affected cases continues to
increase significantly on a daily basis.
The overall mortality rate ranges from2 AJOG MFM MAY 20203% to 4% according to theWorld Health
Organization reports,6 but a higher rate
of patients require admission to the
intensive care unit (ICU).7
It is well known that physiologic
maternal adaptations to pregnancy pre-
dispose pregnant women to a more se-
vere course of pneumonia, with
subsequent higher maternal and fetal
morbidity and mortality,1,8 but there is a
lack of data in the literature about the
effect of CoV infections during preg-
nancy, thus limiting both counseling and
management of these patients.
Objective
The aim of this systematic review was to
report pregnancy and perinatal outcomes
of CoV spectrum infections and partic-
ularly COVID-19 during pregnancy.
Materials and Methods
Search strategy and selection criteria
This review was performed according to
a prioriedesigned protocol recom-
mended for systematic reviews and
meta-analysis.9e11 Medline, Embase,
Cinahl, and Clinicaltrials.gov databases
were searched electronically on March
13, 2020, utilizing combinations of the
relevant medical subject heading
(MeSH) terms, key words, and word
variants for coronavirus or severe acute
respiratory syndrome or SARS orMiddleEast respiratory syndrome or MERS or
COVID-19 and pregnancy. The search
and selection criteria were restricted to
English language. Reference lists of rele-
vant articles and reviews were hand
searched for additional reports. Preferred
Reporting Items for Systematic Reviews
and Meta-Analyses and Meta-Analysis of
Observational Studies in Epidemiology
guidelines were followed.12e14
Inclusion criteria were hospitalized
pregnant women with a confirmed
coronavirus-spectrum illness, defined as
SARS, MERS or COVID-19 infection.
The pregnancy outcomes observed
were as follows:
 Preterm birth (PTB; either before 37
or 34 weeks of gestation).
 Preeclampsia (PE).
 Preterm prelabor rupture of mem-
branes (pPROM).
 Fetal growth restriction (FGR).
 Miscarriage, as defined by the authors.
 Cesarean mode of delivery.
The perinatal outcomes observed
were as follows:
 Fetal distress (as defined by original
authors).
 Apgar score <7 at 5 minutes.
 Neonatal asphyxia (as defined by
original authors).
 Admission to neonatal intensive care
unit (NICU).
 Perinatal death, including both still-
birth and neonatal death.
 Evidence of vertical transmission,
defined as the presence of clinical
signs of mother-to-child transmission
in the antenatal or perinatal period.
Furthermore, we aimed to perform a
subgroup analysis according to the
trimester of pregnancy at infection and
the type of coronavirus.
Data from studies reporting the inci-
dence of these outcomes in pregnancies
with CoV-spectrum infections were
considered eligible for analysis. For the
purpose of the analysis, we included only
full-text articles with data of pregnant
women who already delivered; we
excluded data regarding ongoing preg-
nancies. Furthermore, because these are
TABLE 1
General characteristics of the included studies
Author Year Study location Study period Study design
Pregnancies,
n
Type of
coronavirus
Mean maternal
age, y
Chen et al16 2020 China 2020 Retrospective 9 SARS-CoV-2 29.9
Wang et al7 2020 China 2020 Case report 1 SARS-CoV-2 28.0
Zhu et al18 2020 China 2020 Retrospective 9 SARS-CoV-2 30.9
Li et al19 2020 China 2020 Case report 1 SARS-CoV-2 30.0
Liu et al20a 2020 Hubei, China 2020 Retrospective 11 SARS-CoV-2 32.5
Liu et al21 2020 Guangdong, China 2020 Retrospective 10 SARS-CoV-2 30.5
Alfaraj et al22 2019 Saudi Arabia 2015 Case series 2 MERS-CoV 34.0
Jeong et al23 2017 South Korea 2015 Case report 1 MERS-CoV 39.0
Alserehi et al24 2016 Saudi Arabia NR Case report 1 MERS-CoV 33.0
Assiri et al25 2016 Saudi Arabia 2012e2016 Case series 5 MERS-CoV 30.8
Malik et al26 2016 United Arab Emirates 2013 Case report 1 MERS-CoV 32.0
Park et al27 2016 South Korea 2015 Case report 1 MERS-CoV 39.0
Payne et al28 2014 Jordan 2012 Case report 1 MERS-CoV 39.0
Yudin et al29 2005 Canada NR Case report 1 SARS-CoV 33.0
Wong et al30 2004 Hong Kong, China 2003 Retrospective 12 SARS-CoV 30.6
Lam et al31 2004 China 2003 Retrospective 10 SARS-CoV 31.6
Robertson et al32 2004 USA 2003 Case report 1 SARS-CoV 36.0
Schneider et al33 2004 United States 2003 Case report 1 SARS-CoV NR
Stockman et al34 2004 United States 2003 Case report 1 SARS-CoV 38.0
CoV, coronavirus; CoV-2, novel mutation of CoV; MERS, Middle East respiratory syndrome; NR, not reported; SARS, severe acute respiratory syndrome.
a Preliminary data, before peer review version.
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Systematic Reviewrelatively rare infections occurring dur-
ing pregnancy with the majority of data
coming from studies with small sample
sizes, case reports and case series were
also included in the analysis.
Studies reporting cases of infective
pneumonia or other respiratory disor-
ders during pregnancy caused by other
viral agents were excluded. We also
excluded studies pediatric series on
newborns and children from which
maternal and pregnancy information
could not be extrapolated.
Two authors (D.D.M., G.S.) reviewed
all abstracts independently. Agreement
regarding potential relevance or in-
consistencies was reached by consensus
or resolved by discussion with a third
reviewer (F.D.A.). Full-text copies of
applicable papers were obtained, and the
same reviewers independently extracted
relevant data regarding study characteris-
tics and pregnancy outcome. If more than1 study was published on the same cohort
with identical endpoints, the report con-
taining the most comprehensive infor-
mation on the populationwas included to
avoid overlapping populations.
Data analysis
We used meta-analyses of proportions to
combine data and reported pooled pro-
portions. Funnel plots (displaying the
outcome rate from individual studies vs
their precision [1 per SE]) were carried
out with an exploratory aim. Tests for
funnel plot asymmetry were not used
when the total number of publications
included for each outcome was <10. In
this case, the power of the tests is too low
to distinguish chance from real
asymmetry.
Between-study heterogeneity was
explored using the I2 statistic, which rep-
resents the percentage of between-study
variation that is due to heterogeneityrather than chance. A value of 0% in-
dicates no observed heterogeneity,
whereas I2 values 50% indicate a sub-
stantial level of heterogeneity. In view of
the clinical heterogeneity, a random-effect
model was used to compute the pooled
data analyses. Therefore, polled pro-
portions were used, also given small
numbers, but should not be confused
with raw proportions (rates). A pooled
proportion may not coincide with the
actual raw proportion. All proportion
meta-analyses were carried out by using
StatsDirect version 2.7.9 (StatsDirect, Ltd,
Altrincham, Cheshire, United Kingdom).
Quality assessment of the included
studies was assessed using the methodo-
logical quality and synthesis of case series
and case reports described by Murad
et al.15 According to this tool, each study
is judged on 4 broad perspectives: the
selection of the study groups, the ascer-
tainment and the causality of theMAY 2020 AJOG MFM 3
FIGURE
Systematic review flowchart
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Systematic Reviewoutcome observed, and the reporting of
the case. A study can be awarded a
maximum of 1 star for each numbered
item within the selection and reporting
categories, 2 stars for ascertainment, and
4 stars for comparability.15 Given emer-
gency need for this guidance, Prospective
Register of Systematic Reviews, registra-
tion was not sought.
Results
Study selection and characteristics
Five hundred thirty-eight articles were
identified, 27 were assessed with respect to
their eligibility for inclusion, and 19
studies were included in the systematic
review (Table 1, Figure, and Supplemental
Table 1).
These 19 studies16e34 included 79
pregnancies affected by CoV infections.
The mean maternal age was 34.6 years.
Of the 79 pregnancies affected by CoV4 AJOG MFM MAY 2020infections: 41 (51.9%) were affected by
COVID-19, 12 (15.2%) by MERS, and
26 (32.9%) by SARS.
Clinical symptoms and laboratory
parameters in the overall population of
pregnant with CoV infections are re-
ported in Table 2. An overt diagnosis of
pneumonia was made in 91.8% of cases
(54 of 57) (when available, radiological
findings suggestive for pneumonia are
reported in Supplemental Table 2). The
most common symptom was fever that
affected 82.6% (64 of 76) of women,
followed by cough (57.1%, 44 of 77) and
dyspnea (27%, 21 of 77). Lymphopenia
and elevated liver enzymes were found in
79.8% (40 of 48) and 36.6% (9 of 26) of
cases, respectively.
A total of 34.1% of pregnant women
affected by CoV infections (22 of 70) were
admitted to the ICU, and 26.3% (16 of 69)
requiredmechanical ventilation.Maternaldeath occurred in 12.3% of all reported
CoV-related diseases cases (9 of 79). Of
note, the pooled proportions of admission
to the ICU (9.3% vs 44.6% vs 53.3%),
need for mechanical ventilation (5.4% vs
40.9% vs 40%), and maternal death (0%
vs 28.6% vs 25.8%) were significantly
lower in pregnancies affected by COVID-
19, compared with MERS and SARS,
respectively (Supplemental Table 3).
The majority of women affected by
CoV infections were usually treated first
with broad-spectrum antibiotics in
89.3% of cases (49 of 52) and then with
antiviral therapy and steroids in 67.7%
(37 of 51) and 29.8% (12 of 31) of cases
(Table 3 and Supplemental Table 4).
The results of the quality assessment
of the included studies are presented in
Supplemental Table 5.
Synthesis of the results
In the overall population of pregnancies
infected with CoV, the pooled proportion
of miscarriage for CoV infections was
64.7% (8 of 12, 95% confidence interval
[CI], 37.9-87.3), although reported only
for women affected by SARS in two
studieswithno control group.Thepooled
proportions of PTB<37 and 34 weeks of
gestation were 24.3% (14 of 56, 95% CI,
12.5e38.6) and 21.8% (11 of 56, 95%CI,
12.5e32.9), respectively; pPROM
occurred in 20.7% (6 of 34, 95% CI
9.5e34.9), while the pooled proportions
of pregnancies experiencing PE and FGR
was 16.2% (2 of 19, 95% CI, 4.2e34.1)
and 11.7% (2 of 29, 95% CI, 3.2e24.4),
respectively, although data on FGR come
only from women affected by SARS.
The pooled proportion of cesarean
delivery (CD) was 83.9% (50 of 58, 95%
CI, 73.8e91.9) (Tables 4 and 5). The
pooled proportion of perinatal deathwas
11.1% (5 of 60, 95% CI, 84.8e19.6)
including 3 stillbirths and 2 neonatal
deaths (further details are provided in
Supplemental Table 6). A total of 34.2%
(15 of 44, 95% CI, 20.3e49.5) of fetuses
suffered from fetal distress and 57.2% (3
of 12, 95% CI, 3.6e99.8) of newborns
were admitted to the NICU. The pooled
proportion of Apgar score <7 at 5 mi-
nutes was 6.1% (1 of 48, 95% CI,
1.3e13.9), but no cases of neonatal
asphyxia were reported.
TABLE 2
Pooled proportions of the different clinical symptoms and laboratory parameters in the overall population of
pregnancies infected with CoV infection
Outcome
Studies,
n
Pregnancies,
n/N (%)* I2, %
Pooled
proportions
(95% CI)**
Fever 17 64/76 (84.2%) 8.2 82.57 (74.4e90.2)
Cough 18 44/77 (57.1%) 7.3 57.10 (45.8e68.0)
Dyspnea 18 21/77 (27.3%) 53.2 26.98 (18.2e36.8)
Chest pain 17 3/66 (4.5%) 0 8.61 (3.4e16.0)
Pneumonia 16 54/57 (94.7%) 0 91.84 (84.0e97.2)
Lymphopenia 10 40/48 (83.3%) 49.1 79.87 (60.4e93.9)
Elevated liver enzymes 7 9/26 (34.6%) 0 36.59 (20.4e54.5)
Admission to ICU 18 22/70 (31.4%) 58.1 34.10 (17.5e53.0)
Need for mechanical ventilation 17 16/69 (23.2%) 42.9 26.29 (13.3e41.9)
Maternal death 19 9/79 (11.4%) 0 12.30 (6.3e19.9)
CI, confidence interval; CoV, coronavirus; ICU, intensive care unit; n/N, number of cases per total number of included pregnancies.
* Raw proportions; ** A pooled proportion is calculated by using a random-effect model, and therefore it may not refect the actual raw proportion.
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TABLE 3
Pooled proportions of treatment used in the overall population of pregnancies infected with coronavirus infection
Outcome Studies, n
Pregnancies,
n/N (%)* I2, %
Pooled proportions
(95% CI)**
Antiviral therapya 14 37/51 (72.5%) 50.0 67.66 (47.2e85.1)
Antibiotic therapy 14 49/52 (94.2%) 27.9 89.26 (76.8e97.3)
Steroidsb 12 12/31 (38.7%) 58.6 29.81 8.2e57.9)
CI, confidence interval; n/N, number of cases per total number of included pregnancies.
a Lopinavir/ritonavir or oseltamivir were the most common antiviral agents. Ribavirin was used by Wong et al.30; b Maternal (not fetal) indications; * Raw proportions; ** A pooled proportion is
calculated by using a random-effect model, and therefore it may not refect the actual raw proportion.
Di Mascio et al. Outcome of coronavirus spectrum infections during pregnancy. AJOG MFM 2020.
TABLE 4
Pooled proportions of the different pregnancy outcomes in the overall population of pregnancies infected with
coronavirus infection
Outcome
Studies
(n)
Pregnancies
(n/N) (%)* I2 (%)
Pooled proportions
(95% CI)**
PTB <37 wks 16 14/56 (25%) 25.5 24.30 (12.5e38.6)
PTB <34 wks 16 11/56 (19.6%) 1.9 21.79 (12.5e32.9)
PE 6 2/19 (10.5%) 0 16.21 (4.2e34.1)
pPROM 8 6/34 (17.6%) 0 20.72 (9.5e34.9)
FGR 10 2/29 (6.9%) 0 11.66 (3.2e24.4)
Miscarriage 2 8/12 (66.6%) 0 64.74 (39.90-87.32)
Cesarean delivery 17 50/58 (86.2%) 4.0 83.91 (73.8e91.9)
CI, confidence interval; FGR, fetal growth restriction; n/N, number of cases per total number of included pregnancies; PE, preeclampsia; pPROM, preterm prelabor rupture of membranes; PTB,
preterm birth.
* Raw proportions; ** A pooled proportion is calculated by using a random-effect model, and therefore it may not refect the actual raw proportion.
Di Mascio et al. Outcome of coronavirus spectrum infections during pregnancy. AJOG MFM 2020.
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6 AJOG MFM MAY 2020Finally, none of the newborns showed
signs of vertical transmission during the
follow-up period (Tables 6 and 7).
COVID-19
Six studies16e21 reported information
on COVID-19 infection during
pregnancy. There were no data on
miscarriage for COVID-19 infection
occurring during the first trimester.
The pooled proportions of PTB <37
and 34 weeks of gestation were 41.1%
(14 of 32, 95% CI, 25.6e57.6) and
15% (4 of 32, 95% CI, 3.9e31.7),
respectively. pPROM occurred in
18.8% (5 of 31, 95% CI, 0.8e33.5),
while the pooled proportion of
pregnancies experiencing PE was
14.6% (1 of 10, 95% CI, 0.94e40.34),
with no reported cases of FGR.
The pooled proportion of CD was
91% (38 of 41, 95% CI, 81.0e97.6)
(Table 5). The pooled proportion of
perinatal death was 7% (2 of 41, 95% CI,
1.4e16.3) including 1 stillbirth (2.4%)
and 1 neonatal death (2.4%); 43% of
fetuses (12 of 30, 95% CI, 15.3e73.4)
had fetal distress, and 8.7% of newborns
(1 of 10, 95% CI, 0.01e31.4) were
admitted to the NICU. The pooled pro-
portion of Apgar score <7 at 5 minutes
was 4.5% (1 of 41, 95% CI, 0.4e12.6),
and no case of neonatal asphyxia was
reported. Finally, none of the newborns
showed signs of vertical transmission
during the follow-up period (Table 7).
MERS
Seven studies22e28 reported information
on MERS infection during pregnancy.
There were no data on miscarriage for
MERS infection occurring during the
first trimester. The pooled proportion of
PTB was 32.1% (3 of 11, 95% CI,
10.0e59.8), all occurring before 34
weeks of gestation. Preeclampsia
occurred in 19.1% (1 of 7, 95% CI,
1.1e51.3), respectively, while no case of
pPROM or FGR was reported in these
studies. The pooled proportion of CD
was 61.8% (5 of 8, 95% CI, 32.7e86.9)
(Table 5). The pooled proportion of
perinatal death was 33.2% (3 of 10, 95%,
CI 11.2e59.9) including 2 stillbirths and
1 neonatal death (4 hours after birth of
an extremely preterm infant). There
TABLE 6
Pooled proportions of the different perinatal outcomes in the overall
population of pregnancies infected with coronavirus infection
Outcome Studies (n)
Fetuses/Newborns
(n/N) (%)* I2 (%)
Pooled proportions
(95% CI)**
Fetal distress 13 15/44 (34.1%) 13.6 34.15 (20.3e49.5)
Apgar score <7 12 1/48 (2.1%) 0 6.08 (1.3e13.9)
Neonatal asphyxia 9 0/27 (0%) 0 0 (0e15.7)
Admission to NICU 4 3/12 (25%) 76.3 57.16 (3.6e99.8)
Perinatal death 16 5/60 (8.3%) 0 11.11 (84.8e19.6)
Vertical transmission 16 0/60 (0%) 0 1 (0e10.7)
CI, confidence interval; NICU, neonatal intensive care unit; n/N, number of cases per total number of included pregnancies.
* Raw proportions; ** A pooled proportion is calculated by using a random-effect model, and therefore it may not refect the
actual raw proportion.
Di Mascio et al. Outcome of coronavirus spectrum infections during pregnancy. AJOG MFM 2020.
Systematic Reviewwere no cases of fetal distress, Apgar
score <7 at 5 minutes and neonatal
asphyxia. Two case reports described two
infants admitted to NICU. Finally, none
of the newborns showed signs of vertical
transmission during the follow-up
period (Table 7).
SARS
Six studies29e34 reported information on
SARS infection during pregnancy. TheTABLE 7
Pooled proportions of the different pe
type of viral infection
Outcome
SARS-CoV
Studies
Fetuses/
newborns
(n/N) (%)*
Pooled %
(95% CI)**
Fetal distress 5 3/9 (33.3%) 35.89 (12.
e64.4)
Apgar score
<7
4 0/4 (0%) 0 (0e60.2
Neonatal
asphyxia
4 0/4 (0%) 0 (0e60.2
Admission
to NICU
— — —
Perinatal
death
5 0/9 (0%) 0 (0e31.4
Vertical
transmission
6 0/14 (0%) 0 (0e24e
CI, confidence interval; CoV, coronavirus; CoV-2, novel mutation
included pregnancies; SARS, severe acute respiratory syndrome
* Raw proportions; ** A pooled proportion is calculated by using
Di Mascio et al. Outcome of coronavirus spectrum infectionpooled proportion of first trimester
miscarriage for SARS infection was
64.7% (8 of 12, 95% CI, 37.9e87.3). The
pooled proportions of PTB <37 and 34
weeks of gestationwas 15% (1 of 15, 95%
CI, 0.3e45.6) and 28.9% (4 of 15, 95%
CI, 10.7e51.6), respectively. pPROM
and FGR occurred in 50% (1 of 2, 95%
CI, 0.5e95.3) and 18.5% (2 of 15, 95%
CI, 4.4e39.5), respectively, while no
cases of preeclampsia were reported. Therinatal outcomes explored in the present
MERS-CoV
I2
(%) Studies
Fetuses/
newborns
(n/N) (%)*
Pooled %
(95% CI)**
I2
(%
0 0 4 0/5 (0%) 0 (0e44.5) 0
) 0 3 0/3 (0%) 0 (0e56.9) 0
) 0 2 0/2 (0%) 0 (0e67.0) 0
— 2 2/2 (100%) 100 (33.03e100) 0
) 0 6 3/10 (3%) 33.15 (11.2
e59.9)
0
0) 0 4 0/4 (0%) 0 (0e60.2) 0
of CoV; MERS, Middle East respiratory syndrome; NICU, neonatal in
.
a random-effect model, and therefore it may not refect the actual ra
s during pregnancy. AJOG MFM 2020.pooled proportion of CD was 72.2% (7
of 9, 95% CI, 44.1e93.1) (Table 5). Fetal
distress occurred in 35.9% of pregnan-
cies (3 of 9, 95% CI, 12.0e64.4), while
no case of perinatal death, Apgar score
<7 at 5 minutes, and neonatal asphyxia
was reported. There were no data on
pooled proportions of admission to the
NICU of infants born to infected
mothers. Finally, none of the newborns
showed signs of vertical transmission
during the follow-up period (Table 7).
It was not possible to perform a
comprehensive pooled data synthesis on
the incidence of pregnancy and perinatal
outcomes according to the trimester of
pregnancy at infection because of the
very small number of included studies
for each trimester of pregnancy.
Comment
Main findings
The findings from this systematic review
show that more than 90% of hospitalized
pregnant women affected by CoV in-
fections present radiological signs sug-
gestive for pneumonia, detected either at
chest x-ray or computerized tomography
and the most common symptoms are
fever, cough, and lymphopenia.systematic review according to the
SARS-CoV-2
) Studies
Fetuses/
newborns
(n/N) (%)*
Pooled %
(95% CI)** I2 (%)
4 12/30 (40%) 43.02 (15.3
e73.4)
64.7
5 1/41 (2.4%) 4.53 (0.4
e12.6)
0
3 0/21 (0%) 0 (0e13.5) 0
2 1/10 (1%) 8.71 (0.01
e31.4)
81.3
5 2/41 (4.9%) 7.00 (1.4
e16.3)
0
6 0/42 (0%) 0 (0e9.6) 0
tensive care unit; n/N, number of cases per total number of
w proportion.
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have high rates (and pooled pro-
portions) of PTB before 37 and 34weeks.
Preeclampsia and cesarean delivery are
also more common than in the general
population. The pooled proportion of
perinatal mortality is about 10%, while
the most common adverse perinatal
outcome is fetal distress, with more than
half of the newborns admitted in the
NICU. Importantly, clinical evidence of
vertical transmission was found in none
of the newborns included. However,
these findings should be interpreted with
caution in view of the very small number
of included cases and heterogeneity in
clinical presentation and perinatal
management among the included cases.
Strengths and limitations
To the best of our knowledge, this is the
first systematic review exploring preg-
nancy and perinatal outcomes of CoV
infections occurring during pregnancy.
This comprehensive meta-analysis
included all series published so far on
this topic.
The small number of cases in some of
the included studies, their retrospective
nonrandomized design, and the lack of
standardized criteria for the antenatal
surveillance, management, and timing of
delivery of pregnancies affected by CoV
infections represent the major limita-
tions of this systematic review, thus
making it difficult to draw any
convincing evidence on this clinical
management strategies. Furthermore,
there is a possibility that some patients
were included in more than 1 report,
although 2 authors independently
reviewed all the included studies, care-
fully focusing on the different In-
stitutions reporting outcomes.
Moreover, when focusing on the out-
comes of COVID-19 infection, and
particularly perinatal outcomes, re-
ported data are intuitively limited to a
very short-term follow-up period and
thus infectious that occurred proximate
to the delivery. This has the potential to
overestimate the magnitude of risks such
as PTB and underestimate more longi-
tudinal risks such as FGR.
Additionally, it was not possible to
extrapolate data about the pooled8 AJOG MFM MAY 2020proportions of both spontaneous and
iatrogenic PTB and indications for CD
that was performed in the majority of
cases; furthermore, few outcomes (ie,
fetal distress) were not clearly defined,
thus leading to some discrepancies in the
results, like the pooled proportion of
PTB <34 weeks (15%) and the pooled
proportion of newborns admitted to the
NICU (9%), particularly in COVID-19
infection.
Another limitation of the present re-
view was the lack of stratification of the
analysis according to the gestational age
at CoV infection because of the very
small number of included studies for
each trimester of pregnancy. We cannot
assume that the pooled proportions of
miscarriage (only reported for SARS
infection) and PTB should be attributed
solely to the virus/infection because
there are no comparable control groups
of uninfected women from the same
time. It may be that the stress of the
situation in the community contributed
to some of these outcomes.
Finally, we also included case reports
and case series, thus facing a higher risk
of publication bias and decreasing the
level of the evidence of our findings.
Implications
COVID-19 is the last CoV infection
identified at the end of 2019 inWuhan, a
city in the Hubei Province of China.5
Currently, Europe has become the
epicenter of the COVID-19 pandemic,6
but the infection has spread in more
than 150 countries, leading governments
to adopt rigorousmitigationmeasures to
reduce both the viral spread and its
detrimental effects on health care sys-
tems and therefore on the whole econ-
omy of the countries.35
Despite the relatively low mortality,
one of the main concerns related to
COVID-19 infection is the development
of an acute respiratory distress syn-
drome, often requiring invasive ventila-
tion, that is the clinical epiphenomenon
of the viral pneumonia.6,7
The lack of knowledge about COVID-
19 infection has raised urgent questions
among physicians regarding clinical
management and expected outcomes of
the affected patients, and therefore, thereis currently a compelling need of data to
guide clinical decisions.
Regarding pregnancy, the findings
from this study found that radiological
features suggestive for pneumonia can
be found in almost all of the hospitalized
pregnant women, usually presenting
with fever, cough, and lymphopenia
similar to the nonpregnant population.
Of note, serious conditions requiring
admission to the ICU and mechanical
ventilation are significantly less common
when compared with the 2 previous CoV
infections (MERS and SARS). Similarly,
we found no case of maternal death
related to COVID-19 infection, while
MERS and SARS infections caused a
mortality pooled proportion in pregnant
women ranging from 25% to 30%.
In this systematic review, women
affected by COVID-19 disease had
higher rates of preterm birth, and pre-
eclampsia, while the babies had a 2.4%
rate of stillbirth, a 2.4% rate of neonatal
death, and higher rate of admission to
the NICU.
Furthermore, because all the included
studies reported data on hospitalized
women, the reported rates and pooled
proportions of infection-related adverse
outcomes, including pregnancy and
perinatal outcomes, might not reflect the
overall population of pregnant when
who got infected with SARSe
coronavirus-2, and there may be a
cohort of patients with no or mild
symptoms whose pregnancy outcome is,
as of yet, unknown.36
More importantly, it should be
emphasized that there are no known
neonatal symptoms and therefore no
clinical evidence suggestive for vertical
transmission, particularly when
COVID-19 infection occurs later in
pregnancy. Unfortunately, the lack of
data of first- and early second-trimester
infection does not allow to determine
whether in this case the infection may
cause more severe perinatal outcomes
and how to monitor the pregnancy once
the infection has passed.1
Based on the limited information
from this study, COVID-19 cannot be
considered as an indication for delivery,
and therefore, the timing and mode of
delivery should be individualized
Systematic Reviewaccording tomaternal clinical conditions
or obstetric factors as usual (and not
COVID-19 status alone), and the deci-
sion should involve a multidisciplinary
team including maternal-fetal doctors,
neonatologists, anesthesiologists, and
infective disease specialists.
Conclusions
In summary, with the limited data re-
ported to date, hospitalized mothers
infected with coronavirus infections,
including COVID-19, >90% of whom
also had pneumonia, are at increased
risks of adverse obstetrical outcomes,
compared with the general population
and in particular, COVID-19 infection
was associated with a relatively higher
rates of preterm birth, preeclampsia,
cesarean delivery, and perinatal death.
There have been no published cases of
clinical evidence of vertical transmission.
Evidence is accumulating rapidly, so
these data may need to be updated
soon. -
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